Patents by Inventor Chingwei Vivian LEE

Chingwei Vivian LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240132582
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 25, 2024
    Applicant: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer
    Patent number: 11891437
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 6, 2024
    Assignee: Genentech, Inc.
    Inventors: Amin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
  • Anti-IL-36 antibodies and methods of use thereof
    Patent number: 11884719
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 30, 2024
    Assignee: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230183343
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.
    Type: Application
    Filed: November 18, 2022
    Publication date: June 15, 2023
    Applicant: 23andMe, Inc.
    Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
  • Anti-CD96 antibodies and methods of use thereof
    Patent number: 11555073
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 17, 2023
    Assignee: 23andMe, Inc.
    Inventors: Yu Chen, Chingwei Vivian Lee, Germaine Fuh-Kelly, Zuoan Yi, Yao-ming Huang, Valentine Yeung, Krista Maureen McCutcheon, Samuel Nalle, Augusta Eleanor Broughton, Louise Scharf, Navneet Singh, Tina Thai, Shouhua Xiao
  • OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS
    Publication number: 20210363231
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Application
    Filed: August 3, 2021
    Publication date: November 25, 2021
    Inventors: Amin FAMILI, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Karthikan RAJAGOPAL
  • Conjugates comprising a vascular endothelial growth factor (VEGF) antibody and a hyaluronic acid polymer
    Patent number: 11111291
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 7, 2021
    Assignee: Genetech, Inc.
    Inventors: Amin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20210244815
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: April 14, 2021
    Publication date: August 12, 2021
    Inventors: Chingwei Vivian LEE, Mark S. DENNIS, Germaine FUH
  • Anti-CD3 antibodies and methods of use
    Patent number: 11007267
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Chingwei Vivian Lee, Mark S. Dennis, Germaine Fuh
  • OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
    Publication number: 20210115124
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 22, 2021
    Inventors: Patrick KOENIG, Chingwei Vivian LEE, Karthikan RAJAGOPAL, Amin FAMILI, Germaine FUH
  • Polynucleotides encoding optimized variants of anti-VEGF antibodies
    Patent number: 10906968
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 2, 2021
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • Optimized variants of anti-vegf antibodies and methods of use thereof in treatment
    Patent number: 10899828
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS
    Publication number: 20200222547
    Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: July 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Daniela BUMBACA YADAV
  • ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200199217
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: 23andMe, Inc.
    Inventors: Chingwei Vivian LEE, Germaine FUH-KELLY, Louise SCHARF, Tina THAI, Ashka Bharat PATEL, Shashank BHARILL, Erik Edward KARRER
  • ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200199227
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 25, 2020
    Applicant: 23andMe, Inc.
    Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
  • OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS
    Publication number: 20200002411
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Application
    Filed: September 17, 2019
    Publication date: January 2, 2020
    Inventors: Amin FAMILI, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Karthikan RAJAGOPAL
  • OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
    Publication number: 20190100581
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Application
    Filed: July 12, 2018
    Publication date: April 4, 2019
    Inventors: Patrick KOENIG, Chingwei Vivian LEE, Karthikan RAJAGOPAL, Amin FAMILI, Germaine FUH
  • OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
    Publication number: 20190031750
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 31, 2019
    Inventors: Patrick KOENIG, Chingwei Vivian LEE, Karthikan RAJAGOPAL, Amin FAMILI, Germaine FUH
  • Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
    Patent number: 10072075
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 11, 2018
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20180117152
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 3, 2018
    Inventors: Chingwei Vivian LEE, Mark S. DENNIS, Germaine FUH